Restricted accessLetterFirst published online 2025-12
Comment on Severe Acute Respiratory Failure Associated With Trimethoprim/Sulfamethoxazole Among Adolescent and Young Adults: An Active-comparator Restricted Disproportionality Analysis From the FDA Adverse Event Reporting System (FAERS) Database
AhmadiFChalabianlooNMcArthurE, et al. Severe acute respiratory failure associated with trimethoprim/sulfamethoxazole among adolescent and young adults: an active comparator-restricted disproportionality analysis from the FDA Adverse Event Reporting System (FAERS) database. Ann Pharmacother. 2025;26:10600280251320690. doi: 10.1177/10600280251320690.
2.
TrillenbergPSprengerAMachnerB.Sensitivity and specificity in signal detection with the reporting odds ratio and the information component. Pharmacoepidemiol Drug Saf. 2023;32(8):910-917. doi: 10.1002/pds.5624.
3.
LucasSAilaniJSmithTRAbdrabbohAXueFNavettaMS.Pharmacovigilance: reporting requirements throughout a product’s lifecycle. Ther Adv Drug Saf. 2022;13:20420986221125006. doi: 10.1177/20420986221125006.
4.
Serrano-AriasBAraya-ZúñigaAWaterhouse-GarbanzoJRojas-BarrantesZArguedas-ChacónSZavaleta-MonestelE.A comprehensive review of sulfonamide hypersensitivity: implications for clinical practice. Clin Rev Allergy Immunol. 2023;65(3):433-442. doi: 10.1007/s12016-023-08978-w.
